Blueprint Medicines (NASDAQ:BPMC) Earns “Neutral” Rating from Wedbush
Blueprint Medicines (NASDAQ:BPMC – Get Free Report)‘s stock had its “neutral” rating reaffirmed by analysts at Wedbush in a note issued to investors on Monday, Marketbeat reports. They presently have a $129.00 price target on the biotechnology company’s stock, up from their previous price target of $128.00. Wedbush’s target price suggests a potential upside of […]
More Stories
EU Leaders Agree to Explore Use of Frozen Russian Assets for Ukraine
By Guy Birchall European Union leaders agreed at a summit in Brussels on Dec. 18 to explore financing Ukraine’s 2026–27...
Small Plane Crashes Into New Hampshire Condominiums
By The Associated Press NASHUA, N.H.—A pilot was taken to the hospital with injuries Wednesday after a small plane crashed...
Meta Ordered to Provide User’s Complete Personal Data in Austrian Supreme Court Ruling
By Bill Pan Austria’s highest court has ordered Meta to give an online privacy activist full access to his personal...
6 More Fraud Suspects Indicted in Minnesota, as $18 Billion in Medicaid Billing Is Reviewed
By Janice Hisle U.S. First Assistant Attorney Joe Thompson announced indictments against a half-dozen new suspects in a pair of...
Trump Gives Federal Workers 2 More Days Off: Dec. 24 and 26
By Jackson Richman WASHINGTON—President Donald Trump signed an executive order on Thursday closing the federal government on Dec. 24 and...
Trump Media to Merge With Nuclear Fusion Company TAE in $6 Billion Deal
By Tom Ozimek President Donald Trump’s media company, Trump Media & Technology Group (TMTG), said on Dec. 18 that it...